Comparing 10x Genomics (NASDAQ:TXG) & 111 (NASDAQ:YI)

10x Genomics (NASDAQ:TXG) and 111 (NASDAQ:YI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares 10x Genomics and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-6.77%	-6.89%	-5.34%
111	-0.53%	N/A	-2.72%

Institutional & Insider Ownership

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 43.9% of 111 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares 10x Genomics and 111″s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82 million	4.93	-$43.54 million	($0.35)	-70.86
111	$1.80 billion	0.03	-$2.48 million	($1.00)	-6.81

111 has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

10x Genomics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for 10x Genomics and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	2	10	5	0	2.18
111	1	0	0	0	1.00

10x Genomics currently has a consensus price target of $19.46, indicating a potential downside of 21.51%. Given 10x Genomics’ stronger consensus rating and higher possible upside, equities analysts clearly believe 10x Genomics is more favorable than 111.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.